Risk of Cardiovascular Complications in Patients with Persistent Atrial Fibrillation after Dissolution of a Thrombus in the Left Atrial Appendage

Aim      To compare the incidence of cardiovascular complications (CVC) in patients with persistent atrial fibrillation (AF) following thrombus dissolution in the left atrial appendage (LAA) and in patients with persistent AF without preceding LAA thrombosis.

Material and methods  The main group included 43 patients who had been diagnosed with LAA thrombosis on the first examination, transesophageal echocardiography, and who showed dissolution of the thrombus on a repeated study performed after 7.1+2.0 weeks of the anticoagulant treatment. The control group consisted of 123 patients with a risk score >0 for men without LAA thrombosis and score >1 for women without LAA thrombosis according to the CHA2DS2‑VASc scale. The patients were followed up for 47.3±17.9 months. The following unfavorable outcomes were recorded: all-cause mortality, ischemic stroke or systemic thromboembolism, hemorrhagic stroke or severe bleeding, and myocardial infarction (MI).

Results Unfavorable clinical outcomes were observed in 39.5 % of patients in the main group and in 3.3 % of patients in the control group (p<0.001). Furthermore, the incidence of ischemic stroke (relative risk (RR), 12.9; 95 % confidence interval (CI), 2.89–57.2), and MI (RR, 5.72; 95 % CI, 1.09–30.1) was higher in the main group. However, the number of MI cases in both groups and the number of stroke cases in the control group increased during the entire follow-up period, while the number of stroke cases rapidly increased only during the first year of follow-up.

Conclusion      In patients with persistent AF, the risk of CVC after LAA thrombus dissolution remains significantly higher than in patients with AF without LAA thrombosis.

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics–2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56–528. DOI: 10.1161/CIR.0000000000000659

2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2020;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612

3. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51. DOI: 10.1161/CIR.0000000000000665

4. Lip GYH, Banerjee A, Boriani G, Chiang Cen, Fargo R, Freedman B et al. Antithrombotic Therapy for Atrial Fibrillation. Chest. 2018;154(5):1121–201. DOI: 10.1016/j.chest.2018.07.040

5. Lowe BS, Kusunose K, Motoki H, Varr B, Shrestha K, Whitman C et al. Prognostic Significance of Left Atrial Appendage “Sludge” in Patients with Atrial Fibrillation: A New Transesophageal Echocardiographic Thromboembolic Risk Factor. Journal of the American Society of Echocardiography. 2014;27(11):1176–83. DOI: 10.1016/j.echo.2014.08.016

6. Melduni RM, Gersh BJ, Wysokinski WE, Ammash NM, Friedman PA, Hodge DO et al. Real-Time Pathophysiologic Correlates of Left Atrial Appendage Thrombus in Patients Who Underwent TransesophagealGuided Electrical Cardioversion for Atrial Fibrillation. The American Journal of Cardiology. 2018;121(12):1540–7. DOI: 10.1016/j.amjcard.2018.02.044

7. Krivosheev Yu.S., Bashta D.I., Krasilnikova S.Yu., Vilenskiy L.I., Kolesnikov V.N., Chukov S.Z. et al. Left atrial appendage thrombosis in atrial fibrillation - current status of the problem. Jounal of arrhythmology. 2020;26(4):13–20. DOI: 10.35336/VA-2019-4-13-20

8. Zhan Y, Joza J, Al Rawahi M, Barbosa RS, Samuel M, Bernier M et al. Assessment and Management of the Left Atrial Appendage Thrombus in Patients With Nonvalvular Atrial Fibrillation. Canadian Journal of Cardiology. 2018;34(3):252–61. DOI: 10.1016/j.cjca.2017.12.008

9. Zylla MM, Pohlmeier M, Hess A, Mereles D, Kieser M, Bruckner T et al. Prevalence of Intracardiac Thrombi Under Phenprocoumon, Direct Oral Anticoagulants (Dabigatran and Rivaroxaban), and Bridging Therapy in Patients With Atrial Fibrillation and Flutter. The American Journal of Cardiology. 2015;115(5):635–40. DOI: 10.1016/j.amjcard.2014.12.016

10. Zateyshchikov DA, Brovkin AN, Chistiakov DA, Nosikov VV. Advanced age, low left atrial appendage velocity, and Factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation. Journal of Thrombosis and Thrombolysis. 2010;30(2):192–9. DOI: 10.1007/s11239-010-0440-1

11. Wallace TW, Atwater BD, Daubert JP, Voora D, Crowley AL, Bahnson TD et al. Prevalence and Clinical Characteristics Associated With Left Atrial Appendage Thrombus in Fully Anticoagulated Patients Undergoing Catheter-Directed Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology. 2010;21(8):849–52. DOI: 10.1111/j.1540-8167.2010.01729.x

12. Frenkel D, D’Amato SA, Al-Kazaz M, Markowitz SM, Liu CF, Thomas G et al. Prevalence of Left Atrial Thrombus Detection by Transesophageal Echocardiography. JACC: Clinical Electrophysiology. 2016;2(3):295–303. DOI: 10.1016/j.jacep.2016.01.004

13. Kawabata M, Goya M, Sasaki T, Maeda S, Shirai Y, Nishimura T et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy Warfarin vs. Direct Oral Anticoagulants. Circulation Journal. 2017;81(5):645–51. DOI: 10.1253/circj.CJ-16-1089

14. Mumoli N, Amellone C, Antonelli G, Augello G, Cloro C, D’Alleva A et al. Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel. CJC open. 2020;2(6):641–51. DOI: 10.1016/j.cjco.2020.07.016

15. Bernhardt P, Schmidt H, Hammerstingl C, Luderitz B, Omran H. Atrial Thrombi-A Prospective Follow-up Study over 3 Years with Transesophageal Echocardiography and Cranial Magnetic Resonance Imaging. Echocardiography. 2006;23(5):388–94. DOI: 10.1111/j.1540-8175.2006.00225.x

16. Dawn B, Varma J, Singh P, Longaker RA, Stoddard MF. Cardiovascular death in patients with atrial fibrillation is better predicted by left atrial thrombus and spontaneous echocardiographic contrast as compared with clinical parameters. Journal of the American Society of Echocardiography. 2005;18(3):199–205. DOI: 10.1016/j.echo.2004.12.003

17. Izmozherova N.V., Popov A.A., Bakhtin V.M. Efficacy and safety of anticoagulant treatment for non-valvular atrial fibrillation in multimorbid patients. Kardiologiia. 2020;60(2):61–8. DOI: 10.18087/cardio.2020.2.n524

18. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Själander A. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology. 2016;1(2):172–80. DOI: 10.1001/jamacardio.2016.0199

19. Haas S, ten Cate H, Accetta G, Angchaisuksiri P, Bassand J-P, Camm AJ et al. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLOS ONE. 2016;11(10):e0164076. DOI: 10.1371/journal.pone.0164076

20. Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic Heart Valve Thrombosis. Journal of the American College of Cardiology. 2016;68(24):2670–89. DOI: 10.1016/j.jacc.2016.09.958